Open AccessEvaluation of Galcanezumab for the Prevention of Episodic Migraine
Author(s) -
Virginia L. Stauffer,
David W. Dodick,
Qi Zhang,
Jeffrey N. Carter,
Jessica Ailani,
Robert R. Conley
Publication year - 2018
Publication title -
jama neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.298
H-Index - 231
eISSN - 2168-6157
pISSN - 2168-6149
DOI - 10.1001/jamaneurol.2018.1212
Subject(s) - migraine , discontinuation , medicine , placebo , aura , adverse effect , population , randomized controlled trial , anesthesia , pediatrics , alternative medicine , pathology , environmental health
Migraine is a disabling neurological disease characterized by severe headache attacks. Treatment options reduce migraine frequency for many patients, but adverse effects lead to discontinuation in many patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom